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Nicotine has been reported to be avidly self-administered

LOBELINE COMPOUNDS AS A TREATMENT
FOR PSYCHOSTIMULANT ABUSE AND

by rats (Corrigal et al. 1992, 1994; Donny et al., 1996);

WITHDRAWAL, AND FOR EATING

hoWever, the ability of lobeline to support self

DISORDERS

administration has not been investigated. Based on the
differential effects of lobeline and nicotine in behavioral
studies, it appears that these drugs may not be acting via a
common CNS mechanism, even though lobeline is often

FIELD OF THE INVENTION

The present invention relates to the use of lobeline and

analogs thereof in the treatment of drugs of abuse and
WithdraWal therefrom. The invention also relates to the

10

treatment of eating disorders, such as obesity.

(BoWell and Balfour, 1992; Corrigal et al., 1992, 1994).
Presynaptic nicotinic receptors have been found on dopam
ine (DA)-containing nerve terminals (Giorguieff-Chesselet
et al., 1979; Clarke and Pert, 1985). Nicotine binds to

BACKGROUND OF THE INVENTION

Lobeline (ot-lobeline) is a lipophilic, non-pyridino, alka
loidal constituent of Indian tobacco (Lobelia in?ata). As
shoWn by the following formulas, no obvious structural
resemblance to S(—)nicotine is apparent:

/
\

15

CH3

reported to displace [3H]nicotine binding from central nico
tinic receptors With high affinity (Ki=5—30 nM) (Yamada et
al., 1985; Lippiello and Fernades, 1986; Banerjee and
Abood, 1989; Broussolle et al., 1989).

H

the number of nicotinic receptors in many regions of rat and
mouse brain (Collins et al., 1990; Bhat et al., 1991, 1994;
Marks et al., 1992; Sanderson et al., 1993). An increase in
the number of nicotinic receptors in postmortem human
brain tissue obtained from smokers also has been reported

|

Chronic treatment With nicotine results in an increase in

N

S(—) Nicotine
25
4

OH

3

H‘,

2
8

5

1

¢ ’ '

7

nicotinic receptors With high affinity (Kd=1—7 nM)
(Lippiello and Fernandes, 1986; Reavill et al., 1988; Romm
et al., 1990; Bhat et al., 1991; Loiacono et al., 1993;
Anderson and Arneric, 1994). Also, lobeline has been

20

N

|

considered to be a nicotinic agonist (Decker et al., 1995).
The positive reinforcing effect of nicotine is believed to be
due to the activation of central dopaminergic systems

6

O
7 “ ~

If

10

(BenWell et al., 1988). In contrast, chronic lobeline admin

9

CH3

30

istration did not increase the number of nicotinic receptors
in mouse brain regions in Which increases Were observed

folloWing chronic nicotine administration (Bhat et al.,

1991).
Nicotine evokes DA release in in vitro superfusion studies

Structure-function relationships betWeen nicotine and

35

lobeline do not suggest a common pharmacophore (BarloW

and Johnson, 1989). Nonetheless, lobeline has been reported
to have many nicotine-like effects including tachycardia and

hypertension (Olin et al., 1995), bradycardia and hypoten
sion in urethane and pentobarbital anesthetiZed rats (Sloan et

40

al., 1988), hyperalgesia (Hamann and Martin, 1994), mid
olytic activity (Brioni et al., 1993), and improvement of
learning and memory (Decker et al., 1993). Moreover,
lobeline has been used as a substitution therapy for tobacco

smoking cessation (Nunn-Thompson and Simon, 1989;
Prignot, 1989; Olin et al., 1995); hoWever, its effectiveness
is controversial as re?ected by both positive (Dorsey, 1936;

45

KalyuZhnyy, 1968) and negative reports (Wright and
Littauer, 1937; Nunn-Thompson and Simon, 1989).

(Sakurai et al., 1982; Takano et al, 1983; Grady et al., 1992).
Based on these neurochemical studies, lobeline Was sug

information concerning its long-term usage (Wright and
Littauer, 1937; Olin et al., 1995).

gested to be an agonist at nicotinic receptors. It is difficult to
reconcile that nicotine and lobeline similarly release DA and
55

displace [3H]nicotine binding; hoWever, the observed
upregulation of nicotinic receptors folloWing chronic nico

locomotor activity (Clarke and Kumar, 1983a, 1983b;
Clarke, 1990; Fung and Lau, 1988), and to produce condi
tioned place preference (Shoaib et al., 1984); Fudala et al.,

tine administration is not observed folloWing chronic
lobeline administration.

Earlier studies of the pharmacokinetic properties of

1985) in rats. HoWever, the results of the latter studies are

controversial (Clarke and Fibiger, 1987). In contrast,

1986; Damsma et al., 1989; BraZell et al., 1990; Toth et al,
1992). Nicotine-evoked DA release is calcium-dependent,
mecamylamine-sensitive and mediated by nicotinic recep
tors (Giorguieff-Chesselet et al., 1979; Westfall et al, 1987;
Rapier et al., 1988; Grady et al., 1992). Mecamylamine is a
noncompetitive nicotinic receptor antagonist, Which more
effectively blocks the ion channel of the receptor (Varanda
et al., 1985; Loiacono et al., 1993; Peng et al., 1994). Similar
to nicotine, lobeline has been reported to increase DA
release from superfused rat and mouse striatal synaptosomes

Furthermore, only short-term usage of lobeline as a smoking
deterrent has been recommended due to its acute toxicity
(nausea, severe heartburn and diZZiness) and the lack of

In behavioral studies, nicotine has been shoWn to increase

using striatal slices (Westfall, 1974; Giorguieff-Chesselet et
al., 1979; Westfall et al., 1987; Harsing et al., 1992) and
striatal synaptosomes (Chesselet, 1984; RoWell et al., 1987;
Rapier et al., 1988, 1990; Grady et al., 1992, 1994; RoWell
and Hillebrand, 1992, 1994; RoWell, 1995), and in in vivo
studies using microdialysis in striatum (Imperato et al.,

60

lobeline have centered on its proposed use in the treatment

lobeline does not increase locomotor activity (Stolerman et

of nicotinism. For example, US. Pat. Nos. 5,536,503; 5,486,

al., 1995) or produce conditioned place preference (Fudala

362; 5,403,595; and PCT Publication WO 92/19241 are all
related to a drug delivery system and method for treating

and IWamoto, 1986). Although initially lobeline Was shoWn
to generaliZe to nicotine in discrimination studies (Geller et

al., 1971), most subsequent studies have failed to reproduce

this original ?nding (Schechter and Rosecrans, 1972;
Reavill et al., 1990; Romano and Goldstein, 1980).

nicotine dependence. US. Pat. Nos. 5,414,005; 4,971,079;
65

and 3,901,248 also discuss the use of lobeline in the conteXt

of treating nicotine abuse and/or addiction. A scienti?c
article has studied the actions of morphine, lobeline, and

5,830,904
3

4

other drugs in inducing “analgesia” in rats (S. Hamann et al.
1994). However, these Workers did not equate their ?nding

increase the extracellular concentration of dopamine. Many

of an “analgesic” response for lobeline to a reduction of the
pain response in man, nor did they propose the use of

of amphetamine have been identi?ed.

respects in Which the actions of lobeline are similar to those

lobeline in treating drug abuse, WithdraWal from addiction,

BRIEF DESCRIPTION OF THE FIGURES

and the like.
Similarly, to the present inventors’ knowledge, the use of
lobeline in the treatment of eating disorders has not been

FIGS. 1(A) and 1(B) depicts the time course of nicotine
evoked fractional release (A) and concentration-dependence
of nicotine-evoked total [3H]over?oW (D) from rat striatal

proposed. This is in spite of the Widely accepted ability of
nicotine to suppress appetite (see, e.g., Remington’s Pharm.
Sci, 18th ed., p.891) and the previously proposed associa
tion of obesity With reduced bioavailability of dopamine
(US. Pat. Nos. 5,552,429; 5,576,321; 5,272,144; and 5,468,

755).
SUMMARY OF THE INVENTION

10

slices preloaded With [3H]DA (3,4-dihydroxyphenylethyl-2
[N-3H]-amine). Nicotine Was added to the superfusion

buffer after the second sample (as indicated by the arroW)
and remained in the buffer until the end of the experiment.
The data in FIG. 1A are presented as means:S.E. fractional
release, Which represents the tritium in the sample as a
15
percentage of the total tritium in the slice at the time of
sample collection. The data in FIG. 1B are presented as

In its broadest aspect, the present invention is for a

method of treating an individual for drug dependence,
WithdraWal from drug dependence, or for an eating disorder.

mean:S.E. total [3H]over?oW, Which represents the area
under the curve of the corresponding nicotine concentration
response as a function of time. § P<0.05, different from basal

The method comprises administering to the individual an
amount of a lobeline compound, i.e., lobeline, analogs, and

(5—10 min), When fractional release Was collapsed across

derivatives thereof, including pharmaceutically acceptable

0—0.01 pM and 1—100 pM; **P<0.05, different from 0—0.1
pM and 100 pM; ***P<0.05, different from 0—10 pM;
Duncan’s NeW Multiple Range Test. n=4—9 rats.
FIGS. 2(A) and 2(B) depict the time course of lobeline
evoked fractional release from rat striatal slices preloaded
With [3H]DA. Lobeline Was added to the superfusion buffer
after the collection of the second sample (as indicated by the
arroW) and remained in the buffer until the end of the

nicotine concentration; *P<0.05, signi?cantly different from

salts. The amount of lobeline compound administered is
effective to reduce the individual’s desire for the drug of
abuse or for food. The lobeline compound can be adminis 25
tered alone, combined With an excipient, or coadministered
With a second drug having a similar or synergistic effect. The

compound or composition is preferably administered

subcutaneously, intramuscularly, intravenously,
transdermally, orally, intranasally, or rectally.
The utility of lobeline, analogs, and derivatives thereof,

30

experiment. Data are presented as mean:S.E. fractional

release, Which represents the tritium in the superfusate

e.g., those that form lobeline upon metabolism by the body,

sample as a percentage of the total tritium in the slice at the
time of sample collection. FIG. 2A illustrates the time course

in treating dependencies on drugs of abuse is implicated by
the present studies. In particular, the treatment of dependen
cies on such drugs as cocaine, amphetamines, caffeine,

35

of the fractional release evoked by loW concentrations

(0.01—3 pM) of lobeline, and FIG. 2B illustrates that evoked

phencyclidine, opiates, barbiturates, benZodiaZepines,

by high concentrations (3—100 pM). *P<0.05, different from

cannabinoids, hallucinogens, and alcohol is implicated.

basal out?oW; +P<0.05, different from the peak responses at
25 min for 0.01—3 pM and 30—300 pM; § P<0.05, different
from the peak responses of 0.01—10 pM and 100 pM; #
P<0.05, different from the peak responses of 0.01—30 pM;

Also, the treatment of eating disorders, such as obesity, is

implicated.

40

In a preferred aspect of the invention, the method of

Fisher’s LSD post hoc test. n=6 rats.

treatment reduces an individual’s desire for the drug of
abuse or for food by at least one day. It is also preferred that

the treatment method further comprise administering behav
ior modi?cation counseling to the individual.
Although a lobeline compound of the present invention is
contemplated primarily for use in the treatment of drug
abuse and WithdraWal, and for eating disorders, other uses
are also suggested by the studies discussed herein. Thus,

45

FIG. 3 depicts the concentration-dependence of lobeline
evoked total [3H]over?oW from rat striatal slices preloaded
With [3H]DA. Data are presented as mean:S.E. total [3H]
over?oW, Which represents the area under the curve of the
corresponding lobeline concentration-response as a function

of time. The inset illustrates the total [3H]over?oW evoked

by the loWer concentrations (0.01—1 pM) of lobeline. Con

cognitive disorders, brain trauma, memory loss, psychosis,

trol slices Which Were superfused With buffer in the absence

sleep disorders, obsessive-compulsive disorders, panic

of lobeline did not evoke [3H]over?oW (i.e. fractional

disorders, and related conditions are considered to be sus

release Was not different from basal during the course of

ceptible to treatment With a lobeline compound of the

superfusion). * P<0.05, different from control and each of
the other lobeline concentrations; Duncan’s NeW Multiple

present invention.
As shoWn by the results of the studies described herein,

55

and contrary to conventional belief, lobeline is found to act
at higher concentrations primarily not as a nicotinic agonist,
but by a different mechanism than is observed for nicotine.

While not Wishing to be bound by any particular theory, it
is believed that the lipophilic nature of lobeline permits it to
diffuse passively into neurotransmitter-containing vesicles

lamine to inhibit nicotine (10 pM)-evoked fractional release
of [3H]DA from preloaded rat stratal slices. For clarity of
60

is effective in inducing the release of intracellular dopamine.
The present studies also suggest that lobeline may be
on the cells. Either or both mechanisms can thereby Work to

graphical presentation, only signi?cant effects of the loWest
and highest concentration, 0.01 and 100 pM, respectively, of
mecamylamine are illustrated. Data are presented as
mean:S.E. fractional release as percentage of basal out?oW.
Experiments Were performed as described in Table 2 here
inbeloW. The time course begins at the time of nicotine (10

of cells found in the central nervous system (CNS), Where it

effective in inhibiting uptake of extracellular dopamine by
cells of the CNS, perhaps by blocking dopamine receptors

Range Test. n=6 rats.
FIG. 4 depicts the time course of the effect of mecamy

65

pM) addition to the superfusion buffer containing mecamy
lamine. The control represents fractional release in the
absence of either mecamylamine or nicotine in the super

5,830,904
5

6

fusion buffer. Duncan’s NeW Multiple Range Test revealed
a signi?cant inhibitory effect of 0.01 pM mecamylamine,

loWer alkyl. Whenever a carbonyl-containing substituent is
provided as R1 or R2, it is understood that the carbonyl group
is covalently bonded to the respective O atom appearing in
formula
Thus, in the instances Where the substituent is an

When the data Were collapsed across time of superfusion.
n=8 rats.

alkoxycarbonyl or alkylaminocarbonyl, a carbonate or car

FIG. 5 depicts the effects of nicotine (0.01—1000 pM) and
lobeline (0.01—1000 pM) on rat striatal synaptosomal and

bamate linkage is present in the molecule.
Preferred substituents for R1 and R2 include methylcar

synaptic vesicular [3H]DA uptake. III nicotine, synaptoso
mal [3H]DA uptake; I nicotine, vesicular [3H]DA uptake; 0
lobeline, synaptosomal [3H]DA uptake; . lobeline, vesicu
lar [3H]DA uptake. Data are presented as mean:S.E. per

bonyl (acetyl), phenylcarbonyl (benZoyl), natural fatty acid
groups, e.g., palmitoyl, oleyl, linoleyl, stearyl, and lauryl,
10

centage of total [3H]DA uptake. Total [3H]DA uptake for

as a PEG group in a lobeline prodrug enhance transdermal

synaptosomes and vesicles Was 10919.80 pmol/min/mg and

13401717 pmol/min/mg, respectively. Non-speci?c [3H]
DA uptake in synaptosomal and vesicular experiments Was
2% and 20%, respectively, of total [3H]DA uptake as deter
mined by incubation With 10 pM GBR and incubation at 0°

and polyethyleneglycol (PEG) covalently bonded to the
molecule via a carbonate linkage. Long chain moieties such

15

delivery of the molecule, Which may be metaboliZed to
lobeline and derivatives thereof.
As used herein, the terms “loWer alkyl”, “loWer alkenyl”,
“loWer alkoxy”, and the like, refer to normal, branched and
cyclic hydrocarbyl groups containing 1 to 6 carbon atoms.

C., respectively. Experiments examining the effect of nico

The term “higher alkyl” includes alkyl groups containing 7

tine on synaptosomal uptake included a loW concentration
range (0.001—1 nM), hoWever, no effect Was observed and

to about 20 carbon atoms. The term “aryl” refers to a
hydrocarbon group containing one or more aromatic rings,
optionally substituted With one or more heteroatoms. The

for clarity of graphical presentation these results are not

20

Dunnett’s post hoc test. n=3—6 rats.

term “aralkyl” refers to an aryl group covalently bonded to
a loWer alkyl group.

FIG. 6 depicts the endogenous DA and DOPAC
(dihydroxyphenylacetic acid) content in rat striatal slices

having the above formula may be converted into a different

illustrated. *P<0.05, different from total [3H]DA uptake;

superfused With high concentrations (30—100 pM) of

It is, of course, contemplated that certain lobeline analogs
25

molecule upon metabolism by the body. For example, When

lobeline. Endogenous DA and DOPAC content Were deter

ever an acetyl group is present at R1 and/or R2 in the

mined after 60 min superfusion With various concentrations
of lobeline. Data are presented as mean:S.E. ng/mg protein.

processes, e.g., such as occur in the gastrointestinal tract or

compound, the acetyl group may be removed by metabolic
the liver. The choice of substituents is subject to consider

*P<0.05, different from control, P<0.05, **P<0.001, differ
30

ent from control; Dunnett’s post hoc test. n=8 rats.
DETAILED DESCRIPTION OF THE
INVENTION

As used herein, the term “lobeline” refers to a compound

having the general chemical formula 2-[6-([3

35

hydroxyphenethyl)-1-methyl-2-piperidyl]-acetophenone.
The term “lobeline” as used herein refers to the above
compound in its free form, or as a salt thereof, Which has the

physiological activity addressed. Inasmuch as a compound

having this formula has three chiral centers, eight optical
isomers of the compound can exist. HoWever, particular
optical isomer(s) are not intended herein unless speci?cally

40

either R1 or R2 is H and the other combines With R3 or R4
to form a double bond (i.e., a lobeline compound), and (iii)
both R1 and R2 combine With either R3 or R4 to form a
double bond (i.e., a lobelanine compound). It is also pre
ferred that X in the above formula represents a methyl
group. Preferably, the chirality at the 2 and 6 positions of the
piperidyl ring of the compounds is the same as in naturally

occurring lobeline.
Lobeline, as Well as analogs thereof, can be administered
in its free base form or as a soluble salt. Whenever it is

desired to employ a salt of lobeline or analog, it is preferred
that a soluble salt be employed. Some preferred salts include

mentioned.
The term “lobeline analogs” and equivalents thereof, as
used herein, refers to chemical derivatives of lobeline, such
as those obtained by oxidation or reduction of lobeline,
others obtained by esteri?cation of lobeline and its redox
derivatives, as Well as various substitutions at the N-position
of the piperidinyl group in the lobeline molecule.
Preferred lobeline analogs,, Which may act as prodrugs of

the hydrochloride, hydrobromide, nitrate, sulfate, tartrate,
fumarate, citrate, maleate, ascorbate, lactate, aspartate,
mesylate, benZene sulfonate, propionate and succinate salts.
Also, other anionic moieties such as fatty acid salts can be

used, e.g., palmitate salt.
As used herein, an “effective amount”, and similar usages,
refers to an amount of a drug effective to reduce an indi

lobeline itself When metaboliZed by the body, include those

vidual’s desire for a drug of abuse, or for food.

contemplated by formula (I) (Without regard to chirality):
(I)

ations of toxicity, side effects, dosage, and the like.
Particularly preferred lobeline analogs are those in Which
(i) both R1 and R2 are H (i.e., a lobelanidine compound), (ii)

Apharmaceutical composition containing a lobeline com
pound of the invention is also contemplated, Which may
55

include a conventional additive such as a stabiliZer, buffer,

salt, perservative, ?ller, ?avor enhancer, and the like, as
knoWn to those skilled in the art. Representative buffers

include phosphates, carbonates, citrates, and the like. Exem

plary preservatives include EDTA, EGTA, BHA, BHT, and
60

Where R1 and R2 each independently represents hydrogen,
loWer alkyl, loWer alkenyl, loWer alkylcarbonyl,
arylcarbonyl, aralkylcarbonyl, loWer alkoxycarbonyl, loWer

A composition of the invention may be administered by
inhalation, i.e., intranasally as an aerosol or nasal formula
tion; topically, i.e., in the form of an ointment, cream or

alkylaminocarbonyl, higher alkylcarbonyl, and poly
(alkyleneoxide)carbonyl; R3 and R4 each independently

the like.
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lotion; orally, i.e., in solid or liquid form (tablet, gelcap, time
release capsule, poWder, solution, or suspension in aqueous

represents hydrogen or combines With R1 and R2,

or non-aqueous liquid); intravenously as an infusion or

respectively, to form a double bond; and X represents H or

injection, i.e., as a solution, suspension, or emulsion in a

5,830,904
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pharmaceutically acceptable carrier; transdermally, e.g., via

of the superfusion experiment (FIG. 2). Repeated-measures,

a transdermal patch; rectally, as a suppository, and the like.

tWo-Way ANOVA revealed a signi?cant main effect of

Generally, it is expected that a pharmacologically effec
tive dose of a present compound Will require its adminis
tration in an amount less than 1><10_3 mg/kg of body Weight

lobeline concentration (F7)363=1057.13, P<0.0001), a sig
ni?cant main effect of time (F(1O>363)=132.24, P<0.0001) and
a signi?cant concentration><time interaction (F(7O)363)=
44.85, P<0.0001). LoW concentrations (0.01—1 pM) of

per day. The amount to be administered depends to some

extent on the lipophilicity of the speci?c compound selected,
since it is expected that this property of the compound Will
cause it to partition into fatty deposits of the subject. The
precise amount to be administered can be determined by the

skilled practitioner in vieW of desired dosages, side effects,
the medical history of the patient, and the like. It is antici
pated that the compound Will be administered in an amount

lobeline did not signi?cantly increase fractional release

during the entire superfusion period. Lobeline (3 pM)
10

ranging from about 1><10_5 to about 1><10_3 mg/kg/day.
The present study Was performed to determine the
involvement of nicotinic receptors in lobeline-evoked [3H]
over?oW from rat striatal slices preloaded With [3H]DA. The
calcium-dependency of the effect of lobeline and the ability

evoked by high concentrations (10—100 pM) of lobeline Was
15

of mecamylamine to inhibit the lobeline response Were
determined. To assess the contribution of potential effects on

DA uptake, the effect of nicotine and lobeline to inhibit

[3H]DA uptake into striatal synaptosomes and synaptic
present results of the in vitro superfusion studies, striatal

dopamines (DA) and dihydroxy phenylacetic acid (DOPAC)
25

vitro, and after lobeline administration in vivo.
Effect of nicotine on superfused rat striatal slices preloaded

With [3H]DA
In a concentration-dependent manner, nicotine evoked an
increase in the fractional release of tritium over the time

30

35

action Was not signi?cant (F(8O>42O)=1.22, P>0.05). Frac

data Were collapsed across nicotine concentration, fractional
release, from 30—45 min after nicotine addition, Was not

marked increase in [3H]over?oW evoked by high concen
trations of lobeline (FIG. 3). Repeated-measures, one-Way
40

AN OVA revealed a signi?cant lobeline concentration effect

(F(6>35)=61.55, P< 0.0001). The loWest concentration of
lobeline to evoke a signi?cant increase in total [3H]over?oW
Was 1 pM. As the lobeline concentration Was increased, a
45

signi?cantly greater total [3H]over?oW Was evoked.
Furthermore, a plateau in the concentration-response curve
Was not apparent over the concentration range examined.

period.

Lobeline-induced [3H]over?oW: Lack of calcium

Presentation of the results as nicotine-evoked total [3H]
over?oW accentuates the concentration-dependent nature of

dependency

the response to nicotine (FIG. 1B). Repeated-measures,

Previous studies (Westfall, 1974; Westfall et al., 1987)

one-Way ANOVA revealed a signi?cant nicotine

reported that nicotine (<100 pM)-evoked [3H]over?oW from

concentration effect (F(8>39)=25.77, P<0.0001). The loWest
nicotine concentration Which evoked a signi?cant increase
55

concentration-response curve Was not apparent over the

rat striatal slices preloaded With [3H]over?oW Was calcium
dependent. In order to determine if lobeline-induced [3H]
over?oW Was calcium-dependent, the effect of lobeline Was

determined in a calcium-free superfusion buffer containing

concentration range examined. Higher concentrations of

0.5 mM EGTA (ethylene glycol-bis([3-aminoethyl ether)-N,
N,N‘,N‘-tetraacetic acid (See Table 1). TWo-Way ANOVA

nicotine Were not examined because of the extensive Work

of Westfall and collaborators (Westfall, 1974; Westfall et al.,

1987) indicating that nicotine concentrations higher than

Expression of the results as total [3H]over?oW also
revealed a concentration-dependent effect of lobeline and a

signi?cantly different from basal, despite the presence of
nicotine in the superfusion buffer throughout the superfusion

in [3H]over?oW Was 0.05 pM. A plateau in the

slice, and fractional release returned to basal during the

course of the experiment (FIG. 1A). These results suggest
the potential for depletion of DA storage pools folloWing
superfusion With lobeline at high concentrations.

measures, tWo-Way AN OVA (analysis of variants) revealed
a signi?cant main effect of nicotine concentration (F(8)429)
=29.45, P<0.0001) and a signi?cant main effect of time
tional release peaked Within 10—15 min after the addition of
nicotine to the superfusion buffer. From 10—25 min after the
addition of nicotine, fractional release Was signi?cantly
increased above basal out?oW, When the data Were collapsed
across nicotine concentration. At peak fractional release, the
highest concentration of nicotine examined increased frac
tional release 2-fold above basal. Furthermore, When the

comparison to that observed after superfusion With nicotine.
Peak fractional release after superfusion With 30 and 100 pM
lobeline Was approximately 15% and 30%, respectively, of
the total tritium present in the striatal slice (FIG. 2B).
Furthermore, over the remainder of the superfusion period,
fractional release in superfusate samples continued to be
10—20% of the total tritium in the slice. On the other hand,

peak fractional release induced by the highest concentration
(100 pM) of nicotine Was only 2% of total tritium in the

course of the superfusion experiment (FIG. 1A). Repeated

(F(1O)429)=9.76, P<0.0001), but the concentration><time inter

signi?cantly increased 10 min after the addition of lobeline
to the buffer and remained signi?cantly higher than basal
until the end of the experiment.
Of note is the magnitude of the response to lobeline in

20

vesicle preparations Was also determined. Based on the

content Were also determined after lobeline superfusion in

evoked a signi?cant increase in fractional release 15 and 20
min after its addiction to the buffer. Subsequently, the
fractional release returned toWards basal, despite the con
tinuous presence of lobeline in the buffer. Fractional release

60

revealed a signi?cant main effect of lobeline concentration

100 pM act to release DA from superfused rat striatal slices
by a mechanism Which is not calcium-dependent nor

(Within-group factor, F(3>39)=473.08, P<0.001), hoWever, the

nicotinic-receptor mediated.

signi?cant (betWeen-groups factor, F(1>39)=0.13, P>0.05)

main effect of inclusion of calcium in the buffer Was not

and the interaction term also Was not signi?cant (F(3)39)=

Effect of lobeline on superfused rat striatal slices preloaded

With [3H]DA
Lobeline evoked a marked concentration-dependent
increase in fractional release of tritium over the time course

65

1.64, P>0.05). Thus, the effect of lobeline on [3H]over?oW
Was not altered folloWing removal of calcium from the

superfusion buffer.

5,830,904
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TABLE 1

in these experiments. The effect of lobeline (0.1—100 pM) in
the absence of mecamylamine represented control. Two-way
AN OVA revealed a signi?cant main effect of lobeline con

Lobeline Evokes [3H]Overflow from Rat Striatal Slices Preloaded
with [3H]DA in a Calcium-Independent Manner"
Lobeline
Concentration
0.1
1
10
100

centration (within groups factor, F(4)56)=603.84, P<0.0001);
however, both the main effect of mecamylamine concentra

tion (between-groups factor, F(3)14)=2.79, P>0.05) and the
Control Buffer
0.6
2.0
31.9
198.0

1
1
1
1

lobeline><mecamylamine interaction were not signi?cant

Calcium-Free Buffer

0.4
0.6
2.2
20

0
2.9
45.0
185.0

1
1
1
1

0
0.2
4.2
12.0

(F(12)56)=1.30, P>0.05). Thus, lobeline-evoked [3H]over?ow
was not inhibited by mecamylamine.
10

TABLE 3
Lobeline-evoked [3H]Overflow from Rat Striatal Slices Preloaded
with [3H]DA is Not Inhibited bv Mecamylamine"

*Concentration-response of lobeline was determined using either control
Krebs’ buffer or calcium-free buffer with the addition of 0.5 mM EGTA. Data
are presented as mean 1 SE. total [3H]over?ow, n = 6 rats/group.

Nicotine-evoked and lobeline-evoked [3H]over?ow:

15

mecamylamine antagonism

Concen

tration

In a concentration-dependent manner, mecam lamine sig

ni?cantly inhibited nicotine (10 pM)-evoked [ H]over?ow
Repeated-measures, one-way AN OVA revealed a signi?cant

20

mecamylamine concentration effect (F(5>38)=4.46, P<0.005).
Concentrations of mecamylamine from 0.1—100 pM inhib
ited (57%—91%) the effect of nicotine to evoke [3H]
over?ow.
The time course of the effect of mecamylamine illustrates
the pattern and the extent of the inhibition of the nicotine

0.4
0.5
0.3
0.4

2.0
4.9
2.4
0.7

1
1
1
1

0.6
1.8
0.5
0.1

10.3
10.8
8.2
6.5

1
1
1
1

10
0.8
1.4
1.5
0.9

31.9
32.5
41.0
20.0

1
1
1
1

100
2.2
1.0
6.2
2.0

185.0
180.0
179.5
160.4

1
1
1
1

12
47.6
12.2
30.2

striatal synaptosomes and synaptic vesicles
30

To determine if modulation of DA uptake contributed to

the increase in [3H]over?ow evoked by nicotine or lobeline,

P<0.0001), but the concentrationxtime interaction was not

[3H]DA uptake into striatal synaptosomes and synaptic

signi?cant (F(66>599)=0.97, P>0.05). When the data were
collapsed across time, the lowest concentration of mecamy
lamine to produce a signi?cant inhibition of nicotine’s effect
35

signi?cant, inhibition (36%) of nicotine’s effect produced by

vesicles was determined (FIG. 5). Nicotine did not inhibit
[3H]DA uptake into striatal synaptosomes over the concen
tration range (0.001 nM—100 MM) examined. Before deter
mining the effect of nicotine on synaptic vesicular [3H]DA

uptake, the purity of the isolated synaptic vesicle preparation
was determined by electron microscopy of representative
vesicle preparations. Plain spheroid or ellipsoid synaptic

this low concentration of mecamylamine. Interestingly, the
inhibitory effect of 0.01 pM mecamylamine was not detected
when the results were expressed as total [3H]over?ow (See
40

vesicle pro?les of approximately 50 nm in diameter were the

predominant membrane structures observed. Very few

(2 1%) contaminating membrane fragments were present.

in FIG. 4 for comparison.

The effect of nicotine on [3H]DA uptake into synaptic
vesicles was analyzed by repeated-measures, one-way

TABLE 2
45

from Rat Striatal Slices Preloaded with [3H]DA*

Total [3H]Overflow
5.60
3.57
2.40
1.59
1.02
0.54

1
1
1
1
1
1

1.20
1.52
0.87"
0.64**
0.43**
0.32**

AN OVA which revealed a signi?cant nicotine concentration

effect (F(9>28)=3.30, P<0.05). However, Dunnett’s post hoc
analysis revealed that signi?cant inhibition of uptake only

Mecamylamine Inhibition of Nicotine (10 ,uM)-evoked [3H]Overflow

0
0.01
0.1
1
10
100

1
1
1
1

3

The effect of nicotine and lobeline on [3H]DA uptake into rat

measures, two-way AN OVA revealed a signi?cant main

Table 2). The maximal inhibitory effect of the highest
concentration (100 pM) of mecamylamine is also illustrated

0.6
0.9
0.8
0.5

1

1 SE. total [3H]over?ow. n = 4—6 rats.

effect of mecamylamine concentration (F(6)599)=19.59,

was 0.01 pM. The time course illustrates the small, but

0
1
10
100

0.1

*Slices were superfused with buffer in the absence or presence of mecamy
25 lamine (1-100 ,uM) for 60 min, followed by 60 min superfusion with the
addition of lobeline (0.1-100 ,uM) to the buffer. Data are presented as mean

evoked increase in fractional release (FIG. 4). Repeated
P<0.0001), a signi?cant main effect of time (F(11)599)=4.98,

Lobeline Concentration (MM)

(,uM)

from rat striatal slices preloaded with [3H]DA (See Table 2).

Mecamylamine

Meca

mylamine

50

occurred at very high concentration (1 mM) of nicotine.
Lobeline inhibited [3H]DA uptake into synaptopsomes in
a concentration-dependent manner (FIG. 5). Repeated
measures, one-way AN OVA revealed a signi?cant lobeline

concentration effect (F(9)38)=154.0, P<0.0001). The lowest
concentration of lobeline to produce a signi?cant inhibition

in the synaptosomal preparation was 30 pM. The IC5O for

lamine (0.01-100 ,uM) for 60 min, followed by 60 min superfusion with the

lobeline to inhibit uptake into synaptosomes was 80112 pM.
Moreover, in contrast to nicotine, lobeline potently inhibited

addition of 10 ,uM of nicotine to the buffer containing the various concen
trations of mecamylamine. Data are presented as mean 1 SE. total [3H]

[3H]DA uptake into synaptic vesicles in a concentration
dependent manner (F8)26=28.60, P<0.0001). The lowest con

*Slices were superfused with buffer in the absence or presence of mecamy

55

overflow. Total [3H]overflow for slices superfused in the absence of any drug
was 0.06 1 0.06. Slices superfused with nicotine (10 ,uM) in the absence of
60
mecamylamine were considered control for statistical analysis.
*P < 0.05, one-tailed, different from control;
*"P < 0.05, two-tailed, different from control; Dunnett’s post hoc test. n = 8
rats

The ability of mecamylamine (1—100 pM) to inhibit
lobeline (0.1—100 pM)-evoked total [3H]over?ow is shown
in Table 3. Concentrations of mecamylamine which signi?
cantly inhibited nicotine-evoked [3H]over?ow were utilized

centration of lobeline to produce a signi?cant inhibition was
0.3 pM, and complete inhibition was obtained at 10 pM. The
IC5O value for lobeline to inhibit vesicular uptake was
0.8810001 pM, which was 2-orders of magnitude lower
than that for lobeline-induced inhibition of synaptosomal

[3H]DA uptake. TetrabenaZine (0.001—100 pM), a high
65

af?nity and speci?c inhibitor of the synaptic vesicular
monoamine transporter, signi?cantly inhibited striatal
vesicular [3H]DA uptake in a concentration-dependent man

5,830,904
11

12
dihydroxyphenylethyl(2-[N-3H])amine; speci?c activity,

ner (F 9)28)=23.78, P<0.0001). The IC5O for tetrabenaZine
Was 77.7113 nM, and the lowest concentration of tetra
benaZine Which signi?cantly inhibited vesicular uptake Was
0.07 pM. Complete inhibition Was obtained at 1 pM tetra

25.6 Ci/mmol) Was purchased from NeW England Nuclear

(Boston, Mass.). Dopamine hydrochloride, 3,4
dihydroxyphenylacetic acid (DOPAC), 3,4
dihydroxybenZylamine hydrobromide (DHBA), lobeline
hemisulfate, pargyline hydrochloride, HEPES (N-[2

benaZine. Thus, lobeline Was approximately one order of

magnitude less potent than tetrabenaZine in inhibiting

vesicular [3H]DA uptake.

hydroxyethyl piperaZine]-N‘-[2-ethanesulfonic acid]),

Effect of lobeline on endogenous DA and DOPAC content in

potassium tartrate, adenosine 5‘-triphosphate magnesium

rat striatum

salt (ATP-Mg2+), L(+)tartaric acid and 1-octanesulfonic acid

The marked increase in [3H]over?oW in response to

10

superfusion With high concentrations of lobeline (FIGS. 2
and 3) and the lobeline-induced inhibition of synaptosomal

Glutaraldehyde,
acid Was purchased
osmium
from AnalaR
tetroxide(BHD
and copper
Ltd., Poole,
grids Were
15

purchased from EMS Inc. (Fort Washington, Calif.).
Eponate 12 Was purchased from Ted Pella, Inc. (Redding,
Calif.). TS-2 tissue solubiliZer Was purchased from Research

effect on DA (F(6)41)=15.35, P< 0.0001) and DOPAC

(F(6>4O)=6.90, P<0.0001) content in superfused striatal slices.
Superfusion With loW concentrations (0.1—10 pM) of

Products International (Mount Prospect, Ill.). Acetonitrile
(HPLC grade) Was purchased from EM Science (EM

lobeline did not alter DA or DOPAC content (data not

shoWn); hoWever, When slices Were superfused With high

ot-D-Glucose and sucrose Were purchased from

Aldrich Chemical Co., Inc. (MilWaukee, Wis.). Ascorbic

and vesicular [3H]DA uptake (FIG. 5) suggested that super
fusion With lobeline may deplete striatal DA content. One
Way ANOVA revealed a signi?cant lobeline concentration

sodium salt Were purchased from Sigma Chemical Co. (St.
Louis, Mo

20

Industries, N]

All other chemicals Were purchased from

lobeline concentrations (30—100 pM), lobeline signi?cantly

Fisher Scienti?c (Pittsburgh, Pa.).

depleted endogenous DA content and increased DOPAC
content compared to a control (FIG. 6).
To determine if lobeline-induced depletion of endogenous

Subjects

DA content occurred after in vivo administration of lobeline

Male Sprague-DaWley rats (200—250 g) Were obtained
from Harlan Laboratories (Indianapolis, Ind.) and Were
25

to rats, lobeline Was administered (s.c.) acutely (0, 1, 3, 10,
30 mg/kg), intermittently (0, 3, 10 mg/kg, once daily for
days) or continuously (0, and 30 mg/kg, by osmotic
minipump delivery for 21 days), and rat striata Were
obtained for the determination of endogenous DA and
DOPAC content (See Table 4). TWo-Way AN OVA revealed
that lobeline did not signi?cantly alter either striatal DA

the Division of Lab Animal Resources at the College of

Pharmacy at the University of Kentucky. Experimental
30

In Vivo Administration of Lobeline
35

treatment regimen examined.
TABLE 4
In vivo Administration of Lobeline Does Not Alter DA and DOPAC
Content in Rat Striatum"

40

0

1

3

10

30

739 z 64

756 z 111

761 z 103

841 z 76

665 z 126

743 z 57

ND

778 z 27

800 z 41

ND

Chronic

840 z 72

ND

ND

ND

856 z 144

DOPAC

84 z 12

81 z 12

89 z 15

82 z 8

72 z 10

45

Acute
Inter-

Acute

(ALZET 2mL4 model, ALZA Corporation, Palo Alto, Calif.)
containing 152 mg/ml of lobeline Was implanted so under
ether anesthesia. A How rate of 2.5 pal/hr delivered lobeline
Striata Were obtained for endogenous DA and DOPAC

50
63 r 6

ND

57 r 12

57 r 3

ND

61 r 4

ND

ND

ND

62 r 10

content determination 21 days after osmotic minipump
implantation. Lobeline dose Was expressed in terms of mg of

lobeline hemisulfate salt per kg body Weight.

mittent
Chronic

lobeline (3 and 10 mg/kg) or vehicle Was administered so
once daily for 10 days. Rats Were killed 24 hrs after the last

(30 mg/kg/day) or vehicle continuously for a 21-day period.

mittent

Inter-

For acute administration studies, lobeline (1, 3, 10 and 30
mg/kg) or vehicle (distilled Water) Was administered subcu
taneously (s.c.) acutely, and striata Were obtained 1 hr after
injection for determination of endogenous DA and DOPAC
content. For intermittent chronic administration studies,
injection and striata Were obtained immediately for deter
mination of endogenous DA and DOPAC content. For
continuous chronic administration, an osmotic minipump

Lobeline (mg/kg)

DA

protocols involving the animals Were in strict accordance
With the NIH Guide for the Care and Use of Laboratory
Animals and Were approved by the Institutional Animal Care
and Use Committee at the University of Kentucky.

Example 1

(F(4)58)=0.05, P>0.05) or DOPAC (F(4)58)=0.54, P>0.05)
content. Therefore, lobeline administration in vivo did not
deplete striatal DA content at any dose of lobeline or any

housed tWo per cage With free access to food and Water in

Example 2

[3H]DA Release Assay

*Rat striata Were obtained 1 hr after acute lobeline administration (0, 1-30

mg/kg, s.c.); after intermittent lobeline administration (0,3 and 10 mg/kg, 55
The effect of lobeline and nicotine on [3H]over?oW from
once daily injection for 10 days, s.c.); and after chronic lobeline delivery by
rat striatal slices preloaded With [3H]DA Was determined
osmotic minipump (0 and 30 mg/kg/day for 21 days, s.c.). Data are presented

using a previously published method (DWoskin and

as mean : S.E. ng/mg protein. ND: not determined. n = 6-8 rats/group.

The invention Will noW be discussed by Way of certain

examples, Which illustrate, but do not limit, the invention.

60

EXAMPLES

Zahniser, 1986). Rat striata Were rapidly dissected on ice and
Were sliced using a McIlWain tissue chopper. Slices (500
pm, 6—8 pg) Were incubated in Krebs’ buffer (in mM; 118

NaCl, 4.7 KCl, 1.2 MgCl2, 1.0 NaH2PO4) 1.3 CaCl2, 11.1
ot-D-glucose, 25 NaHCO3, 0.11 L-ascorbic acid, and 0.004
EDTA (ethylenediamine tetraacetic acid), pH 7.4 and satu

Materials

S(—)Nicotine ditartrate, nomifensine maleate, mecamy
lamine hydrochloride, and GBR 12909 Were purchased from
Was purchased from Fluka Chemika-BioChemika

rated With 95% O2/5% CO2) in a metabolic shaker at 34° C.
for 30 min to alloW for recovery of responsiveness. Slices
Were rinsed With 15 ml fresh buffer and then incubated in

(Ronkonkoma, N.Y.). [3H]Dopamine ([3H]DA; 3,4

fresh buffer containing 0.1 pM [3H]DA (6—8 slices/3 ml) for

Research Biochemicals, Inc. (Natick, Mass.). TetrabenaZine

65
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an additional 30 min. Subsequently, slices Were rinsed With

the same concentration of [3H]DA. At the end of the

15 ml fresh buffer and transferred to a glass superfusion
chamber. Slices Were superfused at 1 ml/min With Krebs’

superfusion experiment, slices Were processed in the endog
enous DA and DOPAC content assay described beloW.

buffer (34° C., pH 7.4, aerated With 95% O2/5% CO2)
containing nomifensine (10 MM), a DA uptake inhibitor, and

Example 4
Striatal DA and DOPAC Content Assay

pargyline (10 MM), a monoamine oxidase inhibitor, to ensure

that [3H]over?oW primarily represented [3H]DA, rather than

Striatal slices from superfusion experiments and striatal

[3H]DA metabolites (Cubeddu et al., 1979; Zumstein et al.,
1981; Rapier et al, 1988). After 60 min of superfusion When

tissue from rats administered lobeline or vehicle in in vivo

basal out?ow Was stabiliZed, tWo 5-min samples (5 ml) Were
collected to determine basal [3H]out?oW.

10

For the nicotine or lobeline concentration-response

studies, a single concentration of either nicotine (0.001—100
pM) or lobeline (0.01—100pM) Was added to the superfusion
buffer of individual chambers after the collection of the
second basal sample, and the drug remained in the buffer for

15

slice from the same rat Was superfused in the absence of
drug and served as control. To determine the calcium

(Dubocovich and Zahniser, 1985). An aliquot (500pl) of
0.1M perchloric acid (pH 1.0) containing 0.14—0.29 pM
3,4-dihydroxybenZylamine hydrobromide (DHBA, internal
standard) Was added to 100 mg of striatum and the mixture
Was sonicated With an Ultrasonic Processor (40-Watt Model,

Sonics & Materials, Danbury, Conn.). The homogenate Was
centrifuged at 30,000><g for 10 min at 4° C., and the

60 min or until the end of experiment. Each chamber Was
exposed to only one concentration of nicotine or lobeline.

The concentration-response for each drug Was determined
using a repeated-measures design. In each experiment, one

studies Were assayed for endogenous DA and DOPAC
content by a modi?cation of a previously described method

20

supernatant Was ?ltered (0.2 pm nylon membrane). An
aliquot (50pl) of the ?ltrate (1:1, 1:50, 1:100, 1:200 or 1:500
dilution With 0.1M perchloric acid) Was injected onto the
high pressure liquid chromatograph With electrochemical
detection (HPLC-EC) system. The HPLC-EC system con

dependency of the effect of lobeline, concentration-response

sisted of syringe loading injector (Model 7725, Rheodyne

experiments Were performed as described above, hoWever,
slices Were superfused in the absence of CaCl2, and 0.5 mM

(Beckman, Fullerton, Calif.), ESA ODS ultrasphere C18

L.P., Cotati, Calif.), Beckman Model 116 HPLC pump
25

To determine the ability of mecamylamine to antagoniZe

reverse-phase column (4.6 cm><75 mm, 3 micron particle
siZe, ESA, Bedford, Mass.), and an ESA 5100A coulometric

nicotine-evoked [3H]over?oW, a repeated-measure design

electrochemical detector With a model 5011 detector cell

EGTA Was added to the superfusion buffer.

Was utiliZed also. Individual slices Were superfused With a

single concentration (0.01—100 pM) of mecamylamine for
60 min, folloWed by 60 min of superfusion With nicotine (10
pM) in the presence of the various mecamylamine concen
trations. One slice in each experiment Was superfused in the
absence of mecamylamine to determine the effect of nicotine
alone. A control slice Was superfused With buffer alone. To

determine the ability of mecamylamine to antagoniZe
lobeline-evoked [3H]over?oW, a betWeen-groups design Was

30

performed at room temperature at a How rate of 1 ml/min.

Complete separation of DA and DOPAC and
re-equilibration of the system required 9 min. The retention
35

fusion for 60 min With a range of concentrations (0.1—100

curves. The detection limit of DA and DOPAC Was 0.2 and

0.05 pg/50 pl injected, respectively. Recovery of internal
40

standard Was routinely 75%.

Example 5

pM) of lobeline, a Within-group factor.

[3H]DA Uptake Assay, Striatal Synaptosomal Preparation

At the end of each experiment, each slice Was solubiliZed
With TS-2, and Was incubated at room temperature over

night. The pH and volume of the solubiliZed tissue samples
Were adjusted to those of the superfusate samples. Radio
activity in the superfusate and tissue samples Was deter

time of DA, DOPAC and DHBA standards Was used to

identify the relevant peak. Peak heights Were used to cal
culate the detected amount of compound based on standard

utiliZed. Slices Were superfused for 60 min in the absence or

presence of different concentrations (1—100 MM) of
mecamylamine, a betWeen-group factor, folloWed by super

(E1=+0.05 V, E2 =+0.32 V). The eluent Was 6% acetonitrile,
10 pM EDTA, 1.4 mM 1-octane-sulfonic acid and 76 mM
sodium phosphate monobasic (pH 3.1). All separations Were

45

The uptake of [3H]DA into striatal synaptosomes Was
determined using a modi?cation of a previously published
method (Masserano et al., 1994). The striata from a single rat
Were homogeniZed in 20 ml cold 0.32M sucrose With 5 mM

mined by liquid scintillation counting (Packard model

NaHCO3 (pH 7.4) With 16 up and doWn strokes of a

B1600 TR Scintillation Counter) With an ef?ciency of 59%.
Fractional release for each superfusate sample Was cal

0.003 inches). The homogenate Was centrifuged at 2,000><g

TEFLON pestle homogeniZer (clearance approximately
for 10 min at 4° C. The supernatant Was centrifuged at

culated by dividing the tritium collected in each sample by

20,000><g for 15 min at 4° C. The pellet Was resuspended in

the total tritium present in the tissue at the time of sample

2 ml assay buffer (in mM; 125 NaCl, 5KCl, 1.5 MgSO4, 1.25
CaCl2, 1.5 KH2PO4, 10 ot-D-glucose, 25 HEPES, 0.1
EDTA, 0.1 pargyline, 0.1 ascorbic acid, and saturated With

collection. Fractional release Was expressed as a percentage

of total tritium in the tissue at the time of sample collection.
Basal out?oW Was calculated from the average of the tritium

collected in the tWo 5-min samples just before the addition
of drug. Nicotine or lobeline-evoked [3H]over?oW Was
calculated by summing the increases in collected tritium
resulting from exposure to drug and subtracting the basal

out?oW for the equivalent period of drug exposure.
Example 3
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95% O2/5% CO2, pH 7.4). The ?nal protein concentration
Was 400 pig/ml. The assay Was performed in duplicate in a

total volume of 500 pl. Aliquots (50 pl containing 20 pg of
60

protein) Were incubated With 50 pl of nicotine (?nal con
centration 0.001 nM—100 pM) or 50 pl of lobeline (?nal
concentration, 0.01—1000 pM) in a metabolic shaker at 34°
C. for 10 min. Subsequently, a ?nal DA ([3H]DA/cold DA)

Determination of Endogenous DA and DOPAC Content in

concentration of 0.32 pM Was added to each tube in a total

Striatal Slices FolloWing Superfusion With Lobeline
To determine if lobeline exposure depleted endogenous
DA content in the striatal slices, superfusion experiments

volume of 66 pl, consisting of 16 pl of 0.01 pM [3H]DA and

Were performed exactly as described above, except that
slices Were preloaded With 0.1 pM unlabeled DA, rather than

50 pl of 3 pM unlabelled DA. The incubation continued for
65

10 min at 34° C. The reaction Was terminated by the addition

of 3 ml cold assay buffer (Without 1 mM catechol). Samples
Were rapidly ?ltered through a Whatman GF/B ?lter using a

5,830,904
15

16

Brandel cell harvester (model MP-43RS, Biochemical
Research and Development Laboratories, Inc.,
Gaithersburg, Md.) and the ?lter Was subsequently Washed

collected on copper grids. The sections Were then stained

With saturated uranyl acetate in 70% ethanol and 0.04M lead
citrate. The grids Were vieWed With a Hitachi H-7000

3 times With 4 ml of cold assay buffer containing 1 mM
catechol. Filters Were previously soaked for 2 hrs in the cold

transmission electron microscope (Hitachi, Tokyo, Japan).

assay buffer containing 1 mM catechol. Nonspeci?c uptake

Statistics
Repeated-measures, one-Way AN OVA Was performed to

Was determined in duplicate samples in the presence of 10
pM GBR 12909. Filters Were placed into scintillation vials,
10 ml of scintillation cocktail Was added and radioactivity
Was determined by scintillation spectrometry.

Example 8
analyZe the results of the folloWing experiments: the con
centration effect of nicotine or lobeline on [3H]over?oW, the
10

[3H]DA Uptake, Striatal Synaptic Vesicle Preparation
The uptake of [3H]DA into striatal synaptic vesicles Was

determined using previously published methods (Erickson et
al., 1990). Striata from 3 rats Were pooled and homogeniZed
in 0.32M sucrose (pH 7.5, 500 mg/14 ml) With 10 up and
doWn strokes of a TEFLON pestle (clearance approximately

15

0.009 inches) over a 2 min period. The homogenate Was then

centrifuged at 2,000><g for 10 min at 4° C. and the resulting
supernatant Was centrifuged at 10,000><g for 30 min at 4° C.

ability of mecamylamine to antagoniZe nicotine (10 pM)
evoked [3H]over?oW, and the effect of lobeline on DA and
DOPAC content in striatal slices. TWo-Way AN OVAs Were
used to analyZe the concentration effect of lobeline or
nicotine on the time course of fractional release, to analyZe

Example 6

the calcium-dependency of lobeline-evoked [3H]over?oW
and to analyZe mecamylamine antagonism of lobeline
evoked [3H]over?oW. Inhibition of synaptosomal and
vesicular [3H]DA uptake Were analyZed by repeated
measures, one-Way ANOVA, and by an iterative nonlinear

20

least-squares curve-?tting program (GraphPAD-PRIZM;
GraphPAD, San Diego, Calif.) to obtain IC5O values. Dun

Synaptosomes (buffy coat) Were separated from the under
lying mitochondria and cellular debris (reddish pellet) by

nett’s post hoc test Was used to compare treatment means to

gentle sWirling in 2 ml of 0.32M sucrose. The enriched

Test or Fisher’s LSD post hoc analysis Were used to compare

synaptosome fraction (2.0 ml) Was subjected to osmotic
shock by addition of 7 ml distilled H20 and Was homog

a single control mean. Also, Duncan’s NeW Multiple Range
pairs of treatment means. Duncan’s NeW Multiple Range
25

eniZed With 5 up and doWn strokes of the TEFLON pestle.
The osmolarity Was restored by the addition of 900 pl of
0.25M HEPES and 900 pl of 1.0M neutral potassium-tatrate

the tWo-Way AN OVA’s. Fisher’s LSD poste hoc analysis is
a more conservative test, Which takes into account error

Which cumulates during multiple comparisons of pairs of

buffer (pH 7.5) folloWed by a 20 min centrifugation (20,

means. Fisher’s LSD analysis Was used When the interaction

000><g at 4° C.). The supernatant Was then centrifuged for 60
min (55,000><g at 4° C.). One ml of solution containing 10
mM MgSO4) 0.25M HEPES and 1.0M potassium-tartrate

term Was signi?cant in the tWo-Way AN OVAs, speci?cally
in the post hoc analysis of drug><time interactions. Statistical
signi?cance Was reached When P<0.05 (tWo-tailed, unless

buffer Was added to the supernatant and the suspension Was

otherWise indicated).

centrifuged (100,000><g for 45 min at 4° C.). Immediately

Conclusion

before use, the ?nal pellet Was resuspended in the assay

The results of the present study demonstrate that, similar
to nicotine, lobeline evokes [3H]over?oW from rat striatal

buffer (in mM; 25 HEPES, 100 potassium tartrate, 0.05

EGTA, 0.10 EDTA, 2ATP-Mg2+, 1.7 ascorbic acid, pH 7.4).
Aliquots (160 pl containing 8—10 pg protein) of the resus
pension Were incubated With 20 pl of drug (nicotine, ?nal
concentration 0.001—1000 pM; lobeline, ?nal concentration

slices preloaded With [3H]DA in a concentration-dependent
manner. HoWever, in contrast to nicotine, lobeline-evoked
40

nicotinic agonist, the present results suggest that lobeline

0.001—100 pM) and 20 pl of [3H]DA (?nal concentration 0.3
buffer containing 2 mM MgSO4. Samples Were rapidly
?ltered through Whatman GF/F ?lters using the Brandel cell

[3H]over?oW is calcium-independent and mecamylamine
insensitive. Although lobeline is often thought to be a

0.001—100 MM; or tetrabenaZine, ?nal concentration
pM) for 8 min at 37° C. in a total volume of 200 pl. The
reaction Was terminated by addition 2.5 ml of cold assay

Test Was used When signi?cant one-Way ANOVA’s Were
obtained or When signi?cant main effects Were obtained in

acts to evoke [3H]over?oW via a mechanism other than by
stimulation of nicotinic receptors. Moreover, in contrast to
45

nicotine, lobeline potently inhibits striatal synaptosomal and
vesicular [3H]DA uptake. Thus, lobeline-induced inhibition
of DA uptake and alteration of intracellular DA storage may
contribute to the mechanism responsible for the lobeline

harvester. The ?lters Were then Washed 3 times With 4 ml of

cold assay buffer containing 2mM MgSO4. Filters Were

previously soaked in 0.5% polyethylenimine (PEI) solution

evoked increase in [3H]over?oW from [3H]DA -preloaded

for 2 hr at 4° C. Nonspeci?c uptake Was determined by
incubation of duplicate samples at 0° C. in the absence of
drug. Filters Were placed into scintillation vials, 10 ml of

[3H]over?oW from superfused rat striatial slices preloaded

striatal slices.

In agreement With reports of others, nicotine evoked

With [3H]DA (Westfall, 1974; Giorguieff-Chesselet et al.,

scintillation cocktail Was added to each vial, and radioac

tivity Was determined by scintillation spectrometry.

1979; Westfall et al., 1987; Harsing et al., 1992; Sacaan et
55

Example 7

(Chesselet, 1984; RoWell et al, 1987; Rapier et al., 1988,
1990; Grady et al., 1992; RoWell and Hilelbrand, 1992,
1994; RoWell, 1995). The nicotine concentration range

Electron Microscopy
To con?rm the purity of the isolated synaptic vesicles,
vesicle pellets from rat striata Were processed for electron
microscopy. The pellet Was ?xed for 2 hr With 3.5% glut

60

araldehyde in 0.1M phosphate buffer (pH 7.3). After a brief
rinse in phosphate buffer, the pellet Was post?xed for 2 hr in
1% osmium tetroxide in phosphate buffer. The pellet Was

then dehydrated ?ve times in graded ethanol (50%, 70%,
80%, 90% and 100%), and embedded in Eponate 12 resin.
Ultrathin (60—80 nm) sections Were cut on an Ultracut E

microtome (Reichert-Jung, Inc., Vienna, Austria) and Were

al., 1995) and from rat or mouse striatal synaptosomes

(0.001—100 pM) chosen for the present study Was based on
extensive research demonstrating that at loW concentrations
(<100 MM), the effect of nicotine Was calcium-dependent

and antagoniZed by mecamylamine (i.e., nicotinic receptor
mediated); Whereas at high concentrations (>100 pM), a
65

calcium-independent effect Which Was not antagoniZed by
mecamylamine Was observed (Giorguieff-Chesselet et al.,

1979; Westfall et al., 1987; Rapier et al., 1988, 1990; Grady
et al., 1992).

5,830,904
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In previous studies utilizing the slice superfusion assay,
nicotine Was superfused for only short periods of time (3—10
min) (Giorguieff-Chesselet et al., 1979; Westfall et al., 1987;
Harsing et al., 1992; Sacaan et 211., 1995). Only one of these

reports (Kramer et al, 1989; IZenWasser et al., 1991; RoWell
and Hill, 1993). Using the striatal mince preparation, nico
tine has been reported to inhibit [3H]DA uptake by an
indirect mechanism (IZenWasser et al., 1991); hoWever,

reports (Giorguieff-Chesselet et al., 1979) provided the time

other investigators using the more intact striatal slice prepa

course of the effect of nicotine (1 MM), and in that study,
[3H]over?oW remained elevated for the entire 10-min period

ration Were unable to observe any nicotine-induced inhibi

tion of [3H]DA uptake (RoWell and Hill, 1993).
Interestingly, [3H]DA uptake into [3-NGF-treated PC12 cells

of nicotine exposure. The present study illustrates a com

plete time course of exposure (over a 60 min superfusion
period) to a low range of nicotine concentrations (0.01—100

transfected With the rat DA transporter cDNA Was inhibited
10

22M) (FIG. 1A), and illustrates the time course and pattern of
mecamylamine-induced inhibition of the effect of nicotine,
indicative of nicotinic receptor mediation (FIG. 4). The time

tinic receptors may modulate DA uptake. More recently,
nicotine (0.4 mg/kg) administered so to rats Was observed
to increase the clearance of exogenously applied DA in an in

course illustrates that the peak effect of nicotine Was reached

Within 10—15 min after the start of superfusion With drug.

15

Despite continued superfusion With nicotine, the response

20

(see revieW, BroWnstein and Hoffman, 1994), it is not
surprising that they are differentially sensitive to inhibition
25

The lobeline-induced increase in DA concentration in the

consistent With the lobeline-induced inhibition of vesicular
30

35

trations (10—100 22M) examined (FIGS. 1B and 3).
Additionally, a depletion of endogenous DA and an increase
in endogenous DOPAC Was observed in the striatal slices

superfused With these high concentrations of lobe-line,
indicative of marked DA utiliZation in response to lobeline,

and synaptosomal DA uptake. Notably, the loWest concen
tration of lobeline to signi?cantly evoke [3H]over?oW in the
superfusion assay Was 1 22M, Which is Within the range of
concentrations observed to speci?cally inhibit vesicular DA

[3H]over?oW Was markedly increased (8—34 fold) compared
to the effect of nicotine, particularly at the higher concen

by lobeline.
extracellular space (as re?ected by an increase in [3H]
over?oW in superfusate in the [3H]DA release assay) is

Was different from that of nicotine. The peak effect occurred
10—20 min folloWing the start of lobeline exposure and, at
least at the loW concentrations, the response returned to

basal levels despite continued superfusion With lobeline.
HoWever, the response remained signi?cantly above basal
levels during superfusion With the higher lobeline concen
trations (30—100 MM). Moreover, the effect of lobeline on

sitive to lobeline-induced inhibition than the plasma mem
brane DA transporter, and that both transport processes are
not modulated to any great extent by nicotine. Since these

tWo transporters are structurally and functionally different

[3H]DA-preloaded striatal slices in a concentration
dependent manner. HoWever, as illustrated by the time

course (FIG. 2) and the concentration-response curve (FIG.
3), the pattern and the magnitude of the effect of lobeline

vivo voltammetric study (Hart and Ksir, 1996), suggesting
nicotine-induced enhancement of DA clearance in striatum
in vivo. The results of the present study indicate that the
synaptic vesicular DA transporter is signi?cantly more sen

returned to basal levels Within 25 min, indicative of receptor
desensitiZation. The present ?ndings are of particular inter
est considering that in human smokers, a persistent nicotine

blood level (0.1—pM) has been observed during the Waking
hours of each day (BenoWitZ et al., 1990).
Similar to nicotine, lobeline evoked [3H]over?oW from

by nicotine (IC5O=8 MM), and mecamylamine blocked nico
tine’s effects (Yamashita et al, 1995), suggesting that nico

40

uptake, since higher concentrations (i.e. >30 22M) Were
required to detect the inhibition of synaptosomal DA uptake.
The observation that the lobeline-induced [3H]over?oW is
not calcium-dependent suggests that the released DA origi
nated from cytosolic rather than vesicular pools. Since
lobeline is a very lipophilic compound (BarloW and
Johnson, 1989; Reavill et al, 1990; Bhat et al., 1991), it

and potential toxicity, at least in vitro (FIG. 6). Furthermore,

could easily gain access to the vesicular transporter by

in contrast to nicotine, the effect of lobeline Was found in the

passive entrance into the neuron and its vesicles. Lobeline
induced inhibition of vesicular DA uptake could occur via

present study to be calcium-independent and not inhibited

by mecamylamine. Thus, despite the reported high af?nity of
lobeline for the [3H]nicotine binding site, lobeline evidently

tWo mechanisms, dissipation of the vesicle proton gradients
45

and/or interaction With a substrate site on the vesicular
transporter. Because lobeline is a Weak base, and as a result

evokes [3H]over?oW from rat striatal slices preloaded With
[3H]DA by a mechanism other than stimulation of nicotinic

of the loWer pH inside the vesicle, lobeline could accumulate

receptors.

in synaptic vesicles in its charged form (i.e. protonated).
Once lobeline exceeded the buffering capacity Within the
vesicle, the vesicular pH gradient Would be attenuated With

The present results further demonstrate that, in contrast to

nicotine, lobeline potently inhibits [3H]DA uptake into stri
atal synaptosomes and vesicles. Signi?cant inhibition of
[3H]DA uptake into synaptic vesicles Was observed at a low
concentration of 0.3 pM of lobeline, and the IC5O for this

a resulting decrease in available energy for DA uptake

(Beers et al., 1986; Johnson, 1988). Subsequently,
uncharged DA Would diffuse out of the vesicles in accor
dance With the concentration gradient, such that DA con

effect Was 0.88 22M (FIG. 5). Additionally, at higher con

centrations (230 MM), [3H]DA uptake into striatal synap

55

tosomes Was also signi?cantly inhibited. The IC5O for
lobeline-induced inhibition of synaptosomal uptake Was 80

22M, i.e., tWo orders of magnitude higher than that for
inhibition of uptake into synaptic vesicles. The present
results from the synaptosomal assay are in good agreement

60

With a previous report of lobeline-induced inhibition of

[3H]DA uptake into mouse striatal synaptosomes (Debler et
al., 1988). In the present study, nicotine only inhibited
vesicular [3H]DA uptake at a very high concentration (~1
mM) and no inhibition of synaptosomal [3H]DA uptake Was
observed. The lack of effect of nicotine to inhibit DA uptake

into striatal synaptosomes is in agreement With previous

65

centrations in the cytosol Would increase. Elevation of
cytosolic DA Would promote reverse transport and DA
release from the presynaptic terminal into the extracellular
space. Furthermore, neurotoxicity may result from the

increased cytosolic DA, Which could likely undergo auto
oxidation and enZymatic oxidative metabolism, leading to
the increased formation of DOPAC, hydrogen peroxide, free
radicals, and active quinones (Graham et al., 1978; Slivka
and Cohen, 1985). Thus, lobeline-induced redistribution of
intracellular DA Within the presynaptic terminal Would
result in DA release and potential neurotoxicity.
Taken together, lobeline appears to act in an
amphetamine-like manner as a DA releasing agent. Amphet
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amine is lipophilic, entering neurons by passive diffusion
(Ross and Renyi, 1966; Fischer and Cho, 1989; Liang and
Rutledge, 1982). At loW concentrations, amphetamine enters

effects of these drugs, and the differences in their abilities to

upregulate nicotinic receptors folloWing chronic administra
tion.

Although the present invention has been discussed here
inabove by Way of examples for the purpose of illustration
and clarity of understanding, it should be appreciated that
the scope of the invention is instead de?ned by the appended
claims and equivalents thereof.

neurons via the DA transporter; and as a result, DA is

released into the extracellular space by carrier-mediated

exchange diffusion (Fischer and Cho, 1979; Liang and
Rutldege, 1982), a calcium-independent mechanism Which
is sensitive to DA uptake inhibitors (Hurd and Ungerstedt,
1989; Parker and Cubeddu, 1986; ZacZek et al., 1991; Levi
and Raiteri, 1993). Furthermore, amphetamine is a Weak

substrate site (Schuldiner et al, 1993; GonZaleZ et al., 1994),
to enter synaptic vesicles, and dissipate the vesicular proton
gradient resulting in intracellular redistribution and subse
quent release of neurotransmitter (Knepper et al., 1988;
SulZer and Rayport, 1990; SulZer et al., 1995). In compari

The pertinent disclosures of the references listed beloW
and as discussed above herein are incoporated herein by
reference.
15

son With amphetamine, feW studies have focused on the

20

nicotinic agonist (Decker et al, 1995).

rinic properties,” Medical Pharmacol, 38(17):2933—2935

With high concentrations (30—100 pM) of lobeline resulted

(1989).
BARLOW, R. B. et al., “Relationship betWeen structure
25

in vivo administration (4 mg/kg, sc) to rats (Reavill et al.,
1990). Thus, in the present study, in order to obtain higher
brain concentrations, lobeline Was administered to rats in

30

doses up to 30 mg/kg for 21 days. No effect on endogenous

granule membranes,” J. Biol. Chem, 261:2529—2535

35

mg/kg, ip) and no effect on DA striatal content Was

observed (Westfall et al., 1967). The highly lipophilic nature
of lobeline and its ability to cross the blood-brain barrier

results in a higher brain/plasma ratio compared to nicotine

brain after in vivo administration (as are required in the
superfusion buffer to observe the striatal DA depletion) may
not be achieved due to metabolic/pharmacokinetic factors.
Furthermore, chronic administration of lobeline via osmotic
minipump may not have delivered the expected dose, due to

BEERS, M. F. et al., “Evidence for an ascorbate shuttle
for the transfer of reducing equivalents across chromaf?n

(1986).

treatment regimen of lobeline administration. The present

folloWing s.c. administration (BarloW and Johnson, 1989;
Reavill et al., 1990; Bhat et al., 1991). Due to the physico
chemical characteristics of lobeline, high concentrations in

and nicotine-like activity: X-ray crystal structure analysis of
(—)cytisine and (—)lobeline hydrochloride and a comparison
With (—)nicotine and other nicotine-like compounds,” Br. J.

Pharmacol, 98:799—808 (1989).

DA or DOPAC content Was observed folloWing any dose or

results are in agreement With a previous study in Which
lobeline Was administered acutely at a single dose (10

in rat brain,” Eur. J. Pharmacol, 253:261—267 (1994).
BANERJEE, S. et al., “Nicotine antagonists: phosphoi
nositide turnover and receptor binding to determine musca

The current observation, that superfusion of striatal slices
in signi?cant DA depletion, led us to evaluate striatal DA
content folloWing acute, intermittent and chronic in vivo
lobeline administration to rats. Only one study has reported
a brain concentration (0.6 pM) of lobeline 15 min folloWing

AIZENMAN, E., “Effects of nicotinic agonists on the

NMDA receptor,” Brain Res., 551:355—357 (1991).
ANDERSON, D. J. et al., “Nicotine receptor binding of

[3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine

mechanism of action of lobeline; hoWever, the present
?ndings indicate many similarities in the action of these tWo
drugs, even though lobeline has often been categoriZed as a
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What is claimed is:
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7. The method of claim 1, Wherein the eating disorder
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